Eli Lilly and CompanyvsViking Therapeutics

LLY and VKTX stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

VKTX

Viking Therapeutics, Inc.

$24.77

Value $3.2B

-4.14%
VKTX's page

Eli Lilly and Company (LLY) has a market value of $1.27T and Viking Therapeutics (VKTX) $3.2B. Over the last year, with dividends, LLY moved +29.1% and VKTX -31.3%. Dividend yield: LLY 0.47%, VKTX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.27T

    VKTX$3.2B

    LLY is 402 times VKTX

  • Revenue, 12 months

    LLY$86.5B

    VKTX$0

  • Net income, 12 months

    LLY$27.6B

    VKTX-$627M

  • Operating margin

    LLY–

    VKTX–

  • ROIC

    LLY35.5%

    VKTX-82.4%

    117.9 points apart

  • P/E

    LLY46.1

    VKTX–

  • Dividend yield

    LLY0.5%

    VKTX0.0%

    0.5 points apart

  • 5-year return

    LLY+439.5%

    VKTX+339.2%

    100.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+439.5%

VKTX+339.2%

05001000150020222023202420252026
Returns by period
PeriodLLYWith dividendsVKTXWith dividends
1 year since November 19, 2025+29.1%Price +28.3%-31.3%Price -31.3%
3 years since November 20, 2023+130.0%+32.0% a yearPrice +125.4%+110.5%+28.1% a yearPrice +110.5%
5 years since November 19, 2021+439.5%+40.1% a yearPrice +416.7%+339.2%+34.4% a yearPrice +339.2%
10 years since November 22, 2016+1,962.1%+35.3% a yearPrice +1,672.7%+2,053.9%+35.9% a yearPrice +2,053.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyVKTXViking Therapeutics

Valuation

LLYVKTX
Valuation
Price$1,347.11$24.77
Market value$1.27T$3.2B
Enterprise value (EV)$1.32T$2.4B
P/E46.1–
P/E, 5-year median49.9–
P/B31.65.4
EV/EBIT37.8–
Free cash flow yield1.6%–

Results and growth

LLYVKTX
Results and growth
Revenue, 12 months$86.5B$0
Net income, 12 months$27.6B-$627M
Free cash flow, 12 months$19.7B-$463M
Earnings per share, 12 months$30.81-$5.41
Revenue growth, year on year44.7%–
Revenue growth a year, past+21.6%over 5 years–
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYVKTX
Margins and returns on capital
Gross margin83.6%–
Operating margin––
Net margin31.9%–
ROIC35.5%-82.4%
ROE88.6%-110.0%

Balance sheet

LLYVKTX
Balance sheet
Cash$4.9B$960M
Total debt$49.5B$255M
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYVKTX
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or VKTX

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Viking Therapeutics?

By market value, Eli Lilly and Company ($1.27T) is about 402.3 times Viking Therapeutics ($3.2B), at today's prices.

How did LLY and VKTX stock do over the last 10 years?

Since November 22, 2016, LLY's price moved +1,672.7% and VKTX's +2,053.9%. With dividends: LLY +1,962.1% (+35.3% a year), VKTX +2,053.9% (+35.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or VKTX?

The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for Viking Therapeutics. Over the last twelve months they paid $6.34 and – per share.

Which is the better investment, Eli Lilly and Company or Viking Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.